|
 |
| home > pmps > autumn 2002 > controlled delivery technologies applied to the nutraceutical industry |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Medical professionals and consumers are increasingly viewing nutraceuticals as adjuncts to traditional, pharmaceutical-based therapeutics. The growing awareness of the therapeutic potential of nutraceuticals has prompted the application of pharmaceutical controlled delivery technologies to the nutraceutical industry. While controlled release nutraceuticals have thus far developed to a limited extent for both economic and technical reasons, delivery technologies are being developed to adapt to the unique demands of the nutraceutical market.
Controlled delivery technologies refer to the process of engineering control over the release of a given active ingredient from a device such as a capsule or tablet during its transit through the gastrointestinal tract. Some common terms that are associated with controlled delivery are 'timed', 'extended', 'sustained' and 'prolonged' release. While not all products which use these terms are identical in their rate and extent of release, they are distinguished from 'immediate' release products that do not contain any mechanism for controlling the release of the active ingredient.
The vast majority of nutraceuticals are immediate release products that rapidly dissolve in the stomach once swallowed. Rapid dissolution may effect the nutraceutical's active ingredient in one or more ways, including changes in solubility or structure due to the acidic pH and enzymes of the gastric fluid.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Stephen Turner, Director of Product Development, Michael Hite, Lead Research Associate and Cathy Federici, Research Associate, members of the Research and Product Development group at SCOLR®, Inc
Stephen Turner, Director of Product Development, Michael Hite, Lead Research Associate and Cathy Federici, Research Associate are all members of the Research and Product Development group at SCOLR® Inc, a drug delivery company specialising in the development and application of novel oral drug delivery systems.
Stephen is a graduate of Western Washington University, Michael is a graduate of Amherst College and Cathy a graduate of Swarthmore College. They joined SCOLR® in 1999, 2000 and 2001 respectively.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
